Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Combination of chemotherapy with a tyrosine-kinase inhibitor is effective in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia. Ponatinib is a more potent BCR-ABL1 inhibitor than all other tyrosine-kinase inhibitors and selectively suppresses the resistant T315I clones. We examined the activity and safety of combining chemotherapy with ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia in this continuing phase 2 trial.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Nov 2015

Volume: 16

Issue: 15

Affiliations

[1 ] Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ejabbour@mdanderson.org.

[2 ] Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[3 ] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[4 ] Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Article

Publisher Item ID: S1470-2045(15)00207-7 Mid ID: NIHMS766980

DOI: 10.1016/S1470-2045(15)00207-7

PMC ID: 4816046

PubMed ID: 26432046

SO-VID: 4b2e40d7-7761-415d-8450-b25d861112d4

History

Data availability:

Comments

Comment on this article

scite_

Cited by 88

See all cited by

- Version 1